XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues    
Total revenues $ 87,208 $ 84,117
Costs of revenue (exclusive of amortization and depreciation)    
Total costs of revenue (exclusive of amortization and depreciation) 39,513 41,759
Product development 8,247 10,689
Sales and marketing 5,409 6,592
General and administrative 19,464 19,396
Amortization 6,124 5,869
Depreciation 291 400
Total expenses 79,048 84,705
Operating income (loss) 8,160 (588)
Other income (expense):    
Interest expense (3,382) (4,072)
Other income 144 1,422
Total other expense (3,238) (2,650)
Income (loss) before taxes 4,922 (3,238)
Provision (benefit) for income taxes 4,463 (1,384)
Net income (loss) $ 459 $ (1,854)
Net income (loss) per common share—basic (in dollars per share) $ 0.03 $ (0.13)
Net income (loss) per common share—diluted (in dollars per share) $ 0.03 $ (0.13)
Weighted average shares outstanding used in per common share computations:    
Basic (in shares) 14,370 14,234
Diluted (in shares) 14,370 14,234
Financial Health    
Revenues    
Total revenues $ 56,133 $ 53,439
Costs of revenue (exclusive of amortization and depreciation)    
Total costs of revenue (exclusive of amortization and depreciation) 27,192 29,597
Patient Care    
Revenues    
Total revenues 31,075 30,678
Costs of revenue (exclusive of amortization and depreciation)    
Total costs of revenue (exclusive of amortization and depreciation) $ 12,321 $ 12,162